# EDGAR Filing Document

**Accession Number:** 0001559834
**File Stem:** 0001663577-25-000205
**Filing Date:** 2025-6
**Character Count:** 7315
**Document Hash:** 15170a5874835f02ff44fd0e75856911
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001663577-25-000205.hdr.sgml**: 20250612

**ACCESSION NUMBER**: 0001663577-25-000205

**CONFORMED SUBMISSION TYPE**: SCHEDULE 13D

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20250612

**DATE AS OF CHANGE**: 20250612

**SUBJECT COMPANY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Medinotec Inc.
- **CENTRAL INDEX KEY:** 0001931055
- **STANDARD INDUSTRIAL CLASSIFICATION:** SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 364990343
- **STATE OF INCORPORATION:** NV
- **FISCAL YEAR END:** 0228

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 005-95076
- **FILM NUMBER:** 251042568

**BUSINESS ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** NORTHLANDS DECO PARK, 10 NEW MARKET ST.
- **STREET 2:** STAND 299 AVANT GARDE AVENUE
- **CITY:** JOHANNESBURG
- **NON US STATE TERRITORY:** NORTH RIDING
- **PROVINCE COUNTRY:** T3
- **ZIP:** 2169
- **BUSINESS PHONE:** 27 87 330 2301

**MAIL ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** NORTHLANDS DECO PARK, 10 NEW MARKET ST.
- **STREET 2:** STAND 299 AVANT GARDE AVENUE
- **CITY:** JOHANNESBURG
- **NON US STATE TERRITORY:** NORTH RIDING
- **PROVINCE COUNTRY:** T3
- **ZIP:** 2169
**FILED BY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Vizirgianakis Stavros G.
- **CENTRAL INDEX KEY:** 0001559834

**ORGANIZATION NAME:**

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D

**MAIL ADDRESS:**
- **STREET 1:** C/O XTANT MEDICAL HOLDINGS, INC.
- **STREET 2:** 664 CRUISER LANE
- **CITY:** BELGRADE
- **STATE:** MT
- **ZIP:** 59714

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## SCHEDULE 13D

### Under the Securities Exchange Act of 1934

**Medinotec Inc.**

*(Name of Issuer)*

**COMMON STOCK, $0.001 PER SHARE PAR VALUE**

*(Title of Class of Securities)*

**58500G107**

*(CUSIP Number)*

**Stavros G. Vizirgianakis**<br>C/O XTANT MEDICAL HOLDINGS, INC.<br>664 CRUISER LANE<br>BELGRADE MT 59714<br>27 87 330 2301

*(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)*

**04/16/2025**

*(Date of Event Which Requires Filing of this Statement)*

| **CUSIP No.** | **58500G107** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Stavros G. Vizirgianakis** | Name of reporting person<br>**Stavros G. Vizirgianakis** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**PF** | Source of funds (See Instructions)<br>**PF** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**T3** | Citizenship or place of organization<br>**T3** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**4750179.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**4750179.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**0.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**4750179.00** | Aggregate amount beneficially owned by each reporting person<br>**4750179.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**40.4%** | Percent of class represented by amount in Row (11)<br>**40.4%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**IN** | Type of Reporting Person (See Instructions)<br>**IN** | |

---

**Comment for Reporting Person:** (Item 13) Based on a total of 11,733,750 shares of the Issuer's common stock outstanding as of January 13, 2025 as stated in the Issuer's Form 10-Q for the quarter ended November 30, 2024 filed with the SEC on January 14, 2025.

**Item 1. Security and Issuer**

**(a) Title of Class of Securities:**
COMMON STOCK, $0.001 PER SHARE PAR VALUE

**(b) Name of Issuer:**
Medinotec Inc.

**(c) Address of Issuer's Principal Executive Offices:**
NORTHLANDS DECO PARK, 10 NEW MARKET ST., STAND 299 AVANT GARDE AVENUE, JOHANNESBURG, T3, 2169

Full address as follows: Northlands Deco Park | 10 New Market Street | Stand 299 Avant Garde Avenue | North Riding | Johannesburg | South Africa 2169.

**Item 4. Purpose of Transaction**

The purpose of this Schedule 13D is to report the Beneficial Ownership by the Reporting Person of 4,750,179 shares of common stock or 40.4% of the Issuer's issued and outstanding common stock as of January 13, 2025.

The Reporting Person has no present plans or proposals which relate to or would result in any of the actions specified in clauses (a) through (j) of Item 4. The Reporting Person may, from time to time, determine to acquire additional Common Stock, to dispose of some or all of his Common Stock, discuss the Issuer's business, operations or other affairs with the Issuer's management, board of directors, shareholders, or others or take such other action as he deems appropriate. The Reporting Person reserves the right to change his intentions and adopt plans or proposals in the future that could result in any of the transactions specified in clauses (a) through (j) of Item 4, or any other transaction which the Reporting Person believes could enhance shareholder value.

**Item 5. Interest in Securities of the Issuer**

**(a)**
The Reporting Person is currently the beneficial owner of 4,750,179 shares of common stock of the Issuer, representing approximately 40.4% of the Issuer's common stock (based upon 11,733,750 outstanding shares of common stock as of January 13, 2025 as reported in the Company's Quarterly Report on Form 10-Q filed with the SEC on January 14, 2025).

**(b)**
The Reporting Person has sole voting and dispositive power over the Shares identified in response to Item 5(a) above.

**(c)**
Aside from the following, the Reporting Person has not effected any transactions in shares of common stock in the past 60 days.

**Item 6. Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer.**

Other than as described in this Schedule 13D, the Reporting Person has no contracts, arrangements, understandings or relationships with any other person with respect to any securities of the Issuer.

### SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Stavros G. Vizirgianakis

**Signature:** Stavros G. Vizirgianakis

**Name/Title:** Stavros G. Vizirgianakis / Director

**Date:** 06/12/2025